CIK 0001321834
- Non-accelerated filer
- Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-18 | PharmaCyte Biotech, Inc. 10% owner | Option exercise | +4,982,272 | 5,152,000 | ||
| 2026-11-18 | PharmaCyte Biotech, Inc. 10% owner | Option exercise · Series G Long-Term Warrants | −851,304 | 13,318,344 | ||
| 2026-11-18 | PharmaCyte Biotech, Inc. 10% owner | Other acquisition · Series H Convertible Preferred Stock | +3,000 | 3,000 | ||
| 2025-11-14 | PharmaCyte Biotech, Inc. 10% owner | Purchase · Warrants | +889,865 | 889,865 | ||
| 2025-09-04 | PharmaCyte Biotech, Inc. 10% owner | Purchase · Series H Convertible Preferred Stock | +889,865 | 889,865 |
Page 1 of 1 · 5 trades